ARA 290 Spec. 10mg (10vials/box)

ARA 290 is a derivative of erythropoietin (EPO). In vivo, ARA 290 (0.8 and 8 nmol/kg, i.p.) reduces plasma creatine, urea, and aspartate aminotransferase (AST) levels, markers of renal dysfunction, in a rodent model of renal ischemia-reperfusion injury. It decreases wound area in a rat model of punch biopsy-induced dermal injury and a rat model of decubitus ulcer. ARA 290 (30 µg/kg, i.p.) reduces the latency to find the platform in the Morris water maze in a rat model of cortical impact-induced traumatic brain injury (TBI). It also reduces tactile allodynia in a rat model of neuropathic pain induced by spinal nerve injury (SNI).

WARNING This product is not for human or veterinary use.